SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial

Study limitation reported by the research below: “The overall survival analysis was unplanned; the power calculation was updated post-hoc before data unmasking, which introduces potential methodological bias and should be interpreted with caution.”